With the health care debate continuing, how can investors make money in the sector? Barbara Ryan, managing director and senior pharmaceuticals analyst at Deutsche Bank Securities, and Charles Boorady, health care providers analyst at Citigroup, shared their insights.   Read More

In today's trading session, a total of 50 stocks in the S&P 500 reached new 52-week highs. Here is a look at those companies.   Read More

Unease about the economy drove many investors to snap up defensive stocks. Should you do the same?   Read More

Following are the week’s biggest winners and losers. Find out why shares of Merck and Monsanto popped while Sony and the Semiconductor ETF dropped.   Read More

U.S. stocks finished the week mixed, after reaching new highs for the year earlier on the week.   Read More

Earlier this week I reported that Dr. Allen Taylor who ran the Abbott vs. Merck cholesterol drug study, which Abbott's drug Niaspan won, would only say that ABT has paid him more than $10,000 in lecture and consulting fees. But he wouldn't be any more specific than that.    Read More

Trading desks idle as light volume continues. It started on November 1st — sell-side desks started seeing a drop in trading volume, and it has continued through the month. What gives?    Read More

Stocks opened lower on Tuesday, after a sharp rally in the prior session. Where should investors be looking and how should they play the markets? David Spika, VP and investment strategist at WHG Funds and Bill Smead, CEO and CIO of Smead Capital Management shared their outlooks.    Read More

A smart speech by the Fed chief has given investors the green light.   Read More

Following are the day’s biggest winners and losers. Find out why shares of Dell and FedEx popped while MBIA and Harman International dropped.   Read More